Physician profile
Taylor Davis
NPI 1144869827
$1,210.42
in general payments reported to CMS, 2019-2025
10 companies · $84.09 in 2025
The $84.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $19.29 · 2023: $145 · 2024: $707 · 2025: $84.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.90 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $246.28 | 2023-2025 | Zerbaxa, Dificid, Recarbrio |
| Smith+Nephew, INC. | $147.11 | 2024 | Tc-100 |
| Astrazeneca Pharmaceuticals LP | $138.36 | 2021 | |
| Vifor Pharma, INC. | $116.64 | 2021 | |
| La Jolla Pharmaceutical Company | $106.49 | 2023-2024 | Xacduro, Xerava |
| Melinta Therapeutics, LLC | $56.12 | 2023-2024 | Rezzayo, Kimyrsa, Vabomere |
| Viiv Healthcare Company | $41.76 | 2024-2025 | Rukobia |
| Shionogi INC | $21.06 | 2024 | Fetroja |
| Paratek Pharmaceuticals, INC. | $19.70 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.